Quoin Pharmaceuticals Ltd Stock Net Asset
| QNRX Stock | USD 0.31 0.02 6.06% |
Quoin Pharmaceuticals Ltd fundamentals help investors to digest information that contributes to Quoin Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Quoin Stock. The fundamental analysis module provides a way to measure Quoin Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Quoin Pharmaceuticals stock.
Quoin | Net Asset |
Quoin Pharmaceuticals Ltd Company Net Asset Analysis
Quoin Pharmaceuticals' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Quoin Pharmaceuticals Net Asset | 12.17 M |
Most of Quoin Pharmaceuticals' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Quoin Pharmaceuticals Ltd is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Quoin Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Quoin Pharmaceuticals is extremely important. It helps to project a fair market value of Quoin Stock properly, considering its historical fundamentals such as Net Asset. Since Quoin Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Quoin Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Quoin Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Quoin Total Assets
Total Assets |
|
Based on the recorded statements, Quoin Pharmaceuticals Ltd has a Net Asset of 12.17 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Quoin Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Quoin Pharmaceuticals' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Quoin Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Quoin Pharmaceuticals by comparing valuation metrics of similar companies.Quoin Pharmaceuticals is currently under evaluation in net asset category among its peers.
Quoin Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Quoin Pharmaceuticals from analyzing Quoin Pharmaceuticals' financial statements. These drivers represent accounts that assess Quoin Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Quoin Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 13.6M | 4.7M | 6.9M | 4.4M | 5.1M | 4.8M | |
| Enterprise Value | 8.8M | (210.7K) | 4.0M | 2.0M | 2.3M | 2.2M |
Quoin Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Quoin Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Quoin Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Quoin Pharmaceuticals' value.| Shares | Two Sigma Investments Llc | 2024-09-30 | 0.0 | Bank Of America Corp | 2024-09-30 | 0.0 | Apollon Wealth Management, Llc | 2024-12-31 | 80 K | Renaissance Technologies Corp | 2024-09-30 | 38.7 K | Two Sigma Securities, Llc | 2024-09-30 | 31.9 K | Virtu Financial Llc | 2024-09-30 | 25.2 K | Raymond James Finl Svs Advisors, Inc. | 2024-09-30 | 25.1 K | Rhumbline Advisers | 2024-12-31 | 24.1 K | Ubs Group Ag | 2024-09-30 | 22.8 K | Jpmorgan Chase & Co | 2024-09-30 | 1.3 K | Resources Investment Advisors Inc | 2024-09-30 | 0.0 |
Quoin Fundamentals
| Return On Equity | -1.35 | ||||
| Return On Asset | -0.44 | ||||
| Current Valuation | (7.78 M) | ||||
| Shares Outstanding | 8.19 M | ||||
| Shares Owned By Insiders | 16.80 % | ||||
| Shares Owned By Institutions | 18.89 % | ||||
| Number Of Shares Shorted | 52.82 K | ||||
| Price To Book | 0.46 X | ||||
| EBITDA | (9.27 M) | ||||
| Net Income | (8.69 M) | ||||
| Cash And Equivalents | 2.69 M | ||||
| Cash Per Share | 0.56 X | ||||
| Total Debt | 3.52 K | ||||
| Debt To Equity | 0.47 % | ||||
| Current Ratio | 0.96 X | ||||
| Book Value Per Share | 1.08 X | ||||
| Cash Flow From Operations | (7.86 M) | ||||
| Short Ratio | 0.01 X | ||||
| Earnings Per Share | (3.66) X | ||||
| Target Price | 4.5 | ||||
| Beta | 1.62 | ||||
| Market Capitalization | 2.52 M | ||||
| Total Asset | 12.17 M | ||||
| Retained Earnings | (46.2 M) | ||||
| Working Capital | 7.7 M | ||||
| Net Asset | 12.17 M |
About Quoin Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Quoin Pharmaceuticals Ltd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Quoin Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Quoin Pharmaceuticals Ltd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Quoin Stock Analysis
When running Quoin Pharmaceuticals' price analysis, check to measure Quoin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quoin Pharmaceuticals is operating at the current time. Most of Quoin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Quoin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quoin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Quoin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.